Most oncogenic drivers of NSCLC, including EGFR-activating mutations, ALK rearrangements, ROS1 gene fusions, Kirsten rat arcomaviral oncogene homolog, RET rearrangement, and MET amplification, have all been linked to monoresistance.[77]. Here, RET is linked to non-small cell lung carcinoma.